Stanley Druckenmiller Nektar Therapeutics Transaction History

Duquesne Family Office LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $10.8 Million - $18.4 Million	-1,000,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $16.6 Million - $25.5 Million	1,000,000 New	1,000,000 $20 Million
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $4.49 Million - $8.68 Million	-310,579 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $4.93 Million - $7.18 Million	310,579 New	310,579 $6.7 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $55.1 Million - $125 Million	-1,192,300 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $36.8 Million - $69.6 Million	-641,700 Reduced 34.99%	1,192,300 $127 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $15.4 Million - $40.4 Million	667,900 Added 57.28%	1,834,000 $110 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $20.7 Million - $28 Million	1,166,100	1,166,100 $28 Million

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.